Executive Vice President
Pascale Richetta joins UCB with over 20 years of experience in the pharma and biotech industry. She has acquired impressive commercial experience managing both traditional pharmaceuticals and complex biologics. Her experience and knowledge of markets around the world is key to helping UCB prepare for future product launches. Trained as a medical doctor (MD), Pascale Richetta leads UCB’s Bone Patient Value Unit. One of her main missions is to take UCB’s investigational osteoporosis drug romosozumab through the next steps in its development and prepare for its potential launch upon approval.